FLOWERS FOODS INC (FLO): what the price requires
The current priced-in claim for FLOWERS FOODS INC (FLO) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/FLO
Headline
| Field | Value |
|---|---|
| Ticker | FLO |
| Company | FLOWERS FOODS INC |
| Current price | $8.26/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin today | 5.8% |
| Multiple paid | 12x operating income |
The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.
Solve inputs: computed at a 6% cost of capital with 4% terminal growth over a 5-year stage (computed at the 6% minimum rate; the CAPM rate 5.4% sits below it).
Reconcile: at the x-ray's 9.3% required return this reads ~-0.2%/yr; the models below use their own rates.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | -0.28σ |
| cohort percentile (of 69 peers) | 15 |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 2.98x | 5 | expensive |
| Earnings | 2.23x | 4 | expensive |
| Relative | 0.76x | 3 | justifies |
| Growth | 0.60x | 3 | justifies |
Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.3%); the inversion above states its own rate.
Per-Model Detail (n=15)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | — | — | no | — |
| DCF Exit Multiple | Growth | $13.80 | 0.60x | yes | Exit EV/EBITDA: 10.4x / 12.4x / 14.4x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $9.39 | 0.88x | yes | P/E 22x (static sector reference · 2026-04), scenarios: 18.5x / 22.0x / 25.5x (bear / base = reference held flat / bull), EV/EBITDA 14x |
| Simple DDM | Growth | $29.60 | 0.28x | yes | DPS $1.02, g=5.6% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3% |
| Two-Stage DDM | Growth | $0.19 | 43.47x | yes | Stage 1: -83% for 5yr, Stage 2: 3.5% perpetual (excluded from median) |
| Simple Excess Return | Asset | $3.71 | 2.23x | yes | BV/sh $6.13, ROE (TTM) 5.6%, ke 9.3% |
| Two-Stage Excess Return | Asset | $2.77 | 2.98x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $6.13 | 1.35x | yes | Rev $5.3B, growth 4% (input: historical growth; tapered), Terminal P/S: 0.3x / 0.3x / 0.4x (bear / base = today's held flat / bull, cap 8x) |
| Growth-Adjusted P/E | Relative | — | — | no | — |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $9.02 | 0.92x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.27B × (1−30%) / WACC 4.3% → EPV (no growth) |
| Residual Income | Asset | $2.65 | 3.12x | yes | BV $6.13 + 5yr PV of (ROE (TTM) 5.6% − Kₑ 9.3%) × BV; BV grows 3.6%/yr |
| Graham Number | Asset | $6.95 | 1.19x | yes | √(22.5 × EPS $0.35 × BVPS $6.13) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $10.86 | 0.76x | yes | EBITDA $0.34B × sector EV/EBITDA 14.0x |
| FCF Yield | Earnings | $3.63 | 2.28x | yes | FCF $296.2M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $1.97 | 4.19x | yes | SBC-adj FCF $0.26B (FCF $0.30B − SBC $0.03B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $0.29 | 28.48x | yes | EPS $0.35 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median) |
| ROIC-Justified P/B | Asset | $2.14 | 3.86x | yes | BV $6.13 × (ROIC 1.5% / WACC 4.3%) |
| P/Sales Sector | Relative | $49.62 | 0.17x | yes | Revenue $5.27B × sector P/S 2.0x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | $3.78 | 2.19x | yes | EPS $0.35 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $1.7b |
| Net debt / NOPAT (after-tax) | 7.53x |
| Net debt / operating income (pre-tax) | 5.27x |
| Interest coverage | 4.0x |
| Share count CAGR (buyback) | -0.1% |
| Burning cash | no |
Bullet Takeaways
The counterintuitive part of Flowers Foods is the multiple. At about $7.78 the stock trades near 11 times company-wide operating income, low enough that the price sits below what even a steady decline in operating profit would warrant. The market is not pricing slow growth; it is pricing erosion.
The business behind that price is one of the two largest packaged-bakery companies in the country, with brands like Nature's Own and Wonder, generating real free cash flow. But volumes have been falling, and management has reset the dividend to about $0.50 a year, a deliberate cut to prioritize paying down debt rather than a sign of distress in the payout.
The tension is straightforward. Flowers still earns money and throws off cash, but the core bread category is shrinking under GLP-1 weight-loss drugs, low-carb diets, and aggressive private label. A cheap multiple on a declining base is the textbook setup for a value trap, and the burden of proof is on volumes stabilizing.
Bull Case
The surprising thing about Flowers Foods is that a profitable, cash-generative, top-two player in its category trades at roughly 11 times operating income, a multiple normally reserved for businesses the market expects to shrink meaningfully. That gap between the quality of the franchise and the price is the bull case. Flowers is one of the largest packaged-bakery companies in the United States; its own filing describes a baking industry that "consists of Bimbo Bakeries USA, Flowers Foods, and The Campbell's Company, under the Pepperidge Farm brand, along with a number of smaller independent" players [FY2025 10-K, accession 0001193125-26-071441]. Being one of three at scale in a national fresh-bread business is a durable position, not a fading one.
The brand strength is real and measurable. The filing notes that the Wonder brand "enjoys 93% brand awareness" and that "Wonder's Classic White loaf is the #2 UPC in the white loaf segment" [FY2025 10-K, accession 0001193125-26-071441]. Brands with that kind of recognition, paired with a direct-store-delivery distribution network that is hard for a private-label competitor to replicate, give Flowers pricing power even in a soft volume environment. The company has leaned into the better-for-you shift with the Simple Mills acquisition, adding a faster-growing, premium platform on top of the legacy loaf business.
The cash story supports patience. Flowers generates meaningful free cash flow, the X-ray FCF-yield and earnings-power frames land near or above the current price, and management has reaffirmed full-year 2026 guidance of net sales between $5.163 billion and $5.267 billion, adjusted EBITDA of $465 million to $495 million, and adjusted diluted earnings of $0.80 to $0.90 a share. The dividend reset to roughly $0.50 a year is a choice to deleverage toward a net-debt-to-EBITDA target below three times by fiscal 2027, which strengthens the balance sheet rather than signaling that the cash has dried up. At this price the stock still pays a high single-digit to double-digit yield while the company repairs its leverage.
Bear Case
The bear case is a sector-cycle case, and the cycle here may be structural rather than temporary. The fresh-bread category is not growing, and arguably shrinking, for reasons that have nothing to do with Flowers' execution. GLP-1 weight-loss drugs are suppressing appetite and carbohydrate consumption across the population, a long-running consumer shift toward lower-carb diets is eroding demand for traditional bread, and the categories are saturated. When the question is whether current earnings are peak or sustainable, the honest answer for a bread company facing a demand headwind from a new class of drugs is that the trend points down, and the recent results confirm it: first-quarter 2026 net income fell about 21% to $42.1 million even as net sales edged up 1.1%, because the increase came from the Simple Mills acquisition and pricing, not from volume.
Private label is the second blade of the scissors. In a weak-volume category, retailers push their own cheaper store brands, and the branded player has to choose between defending share with price, which hurts margin, or holding price and ceding volume. The filing is explicit that inflation has tested this, warning that a failure "to raise the prices of our products enough to keep up with the rate of inflation" would "reduce our profit margins" [FY2025 10-K, accession 0001193125-26-071441]. Analysts have flagged exactly this dynamic; Truist cut estimates through fiscal 2027 citing inconsistent execution and intensifying private-label competition. Pricing has carried the top line, but pricing power eventually runs out when volumes keep falling.
The balance sheet narrows the room to maneuver. Flowers carries substantial debt, with net debt running many times operating profit and interest coverage around two, which is why the dividend was cut to fund deleveraging in the first place. Higher interest expense already contributed to the earnings decline. A cheap multiple on a business with falling volumes, margin pressure from private label, and a leveraged balance sheet is the classic value-trap configuration: cheap because of what is deteriorating, and capable of staying cheap or getting cheaper if volumes do not stabilize.
Valuation
Flowers is valued as a whole company off its operating income, and the result is a bound rather than a clean solve. At about $7.78 (June 27, 2026) the price works out to roughly 11 times company-wide operating profit, a multiple so low that the price sits below what even a sustained operating-profit decline of around 5% a year would warrant. The framework deliberately states this as a bound: the price is beyond, on the cheap side, of what an ordinary decline would justify. The market is pricing the business as a structural shrinker, not a slow grower.
The X-ray is split, which is what makes the name interesting and dangerous at once. The earnings-power and FCF-yield frames land near or above the price, reflecting the real cash the business still produces, and the relative and DCF-exit-multiple frames also sit above the price on a sector-typical multiple. But the asset-based methods land below the price, because trailing return on equity around 5.6% is below the cost of equity, so the excess-return and residual-income frames give the equity little credit. The characterization is that relative-multiple and growth-DCF say the price is supportable while asset-based and earnings-power-on-book say it is expensive relative to the returns the company currently earns.
The resolution depends entirely on whether the volume decline stabilizes. If Flowers holds its cash generation roughly flat, the cash-based methods are right and the stock is cheap. If volumes keep eroding and pricing power fades, normalized earnings drift toward the lower asset-based anchors and the cheap multiple was cheap for a reason. The dividend reset to roughly $0.50 a year removes one source of balance-sheet strain, which buys time, but it does not answer the demand question that drives the valuation.
Catalysts
The most recent catalyst was the first-quarter 2026 report, covering the 16-week period ended April 25, 2026, where Flowers posted net sales up 1.1% to $1.572 billion but net income down about 21% to $42.1 million, with diluted earnings of $0.20 and adjusted diluted earnings of $0.29. The same release carried two important decisions: management reaffirmed full-year 2026 guidance of net sales between $5.163 billion and $5.267 billion, adjusted EBITDA of $465 million to $495 million, and adjusted diluted earnings of $0.80 to $0.90, and the board reset the dividend to a roughly $0.50 annual rate to prioritize deleveraging toward a net-debt-to-EBITDA target below three times by fiscal 2027.
The forward catalysts cluster around volume and integration. The key checkpoint each quarter is whether core branded volume stabilizes, since pricing and the Simple Mills acquisition have been doing the work the volume base is not. Progress on integrating Simple Mills and growing its better-for-you platform is the offset management is counting on. Debt reduction against the fiscal 2027 leverage target is the other measurable milestone.
Sentiment is cautious. Truist reduced sales and earnings estimates through fiscal 2027, citing inconsistent execution and intensifying private-label competition, and the broader narrative around GLP-1 drugs pressuring bakery demand remains an overhang. The watch items are clear: branded volume trends, the pace of private-label share gains in the category, input-cost inflation against pricing, and the trajectory of the deleveraging plan.
Sources: Flowers Foods Q1 2026 8-K, SEC; Flowers Foods Q1 2026 results, dividend reset, StockTitan; Flowers Foods FY2026 guidance, Ticker Report; FLO under GLP-1 and consumer pressure, Yahoo Finance; FLO private-label, execution pressure, Yahoo Finance.
Peer Cohorts (Per Segment, With Filing Citations)
Bakery (single reportable segment) (reported)
- CAG (CONAGRA BRANDS, INC.)
- (no filing in the citation store)
- CPB (THE CAMPBELL'S COMPANY)
- (no filing in the citation store)
- POST (Post Holdings, Inc.)
- (no filing in the citation store)
- SJM (THE J. M. SMUCKER COMPANY)
- (no filing in the citation store)
- GIS (GENERAL MILLS INC)
- (no filing in the citation store)
- KHC (Kraft Heinz Co)
- (no filing in the citation store)
- MZTI (The Marzetti Company)
- (no filing in the citation store)
- HRL (HORMEL FOODS CORPORATION)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.